Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy

Ultrasound in Medicine and Biology

Volumn 29, Issue 2, 2003, Pages 209-213

  Zardi, Enrico Maria ^a   Picardi, Antonio ^a   Ambrosino, Giovanni ^b   Serio, Angelo ^c   Costantino, Sebastiano ^a   Dobrina, Aldo ^d  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Arterial resistance index; Color Doppler ultrasound; Iloprost; Interlobar renal artery; Portal flow velocity and volume; Portal hypertension

Indexed keywords

MEDICAL APPLICATIONS; MICROCIRCULATION; PATIENT TREATMENT;

PORTAL FLOW VELOCITY;

ULTRASONICS;

ILOPROST; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DISEASE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; KIDNEY BLOOD FLOW; LEG DISEASE; MALE; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RENAL ARTERY; STATISTICAL SIGNIFICANCE; VASCULAR RESISTANCE;

EID: 0037298690     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-5629(02)00726-3     Document Type: Article

References (17)

1. Barst R.J., Rubin Lj., Long W.A., et al. A comparison of continuous IV epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-302.
2. Barst R.J. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart. 77:1997;299-301.
3. Belch J. Raynaud's phenomenon. Cardiovasc Res. 33:1997;25-30.
4. Bosch J., García-Pagán J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 32:(Suppl. 1):2000;141-156.
5. Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia. Therapie. 46:1991;319-322.
6. Fiessinger J.N., Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet. 335:1990;555-557.
7. Kawada N., Tran-Thi T.A., Klein H., Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Eur J Biochem. 213:1993;815-823.
8. Manasia A., Kang H., Hannon E., et al. Effects of the stable prostacyclin analogue Iloprost on mesenteric blood flow in porcine endotoxic shock. Crit Care Med. 25:1997;1222-1227.
9. Moriyasu F., Ban N., Nishida O., et al. Clinical application of an ultrasonic duplex system in the quantitative measurement of portal blood flow. JCU. 14:1986;579-588.
10. Oberender H., Krais T., Schafer M., Belcher G. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD). Adv Prostaglandin Thromboxane Leukot Res. 19:1989;311-316.
11. Pourcelot L. Vélocimetrie ultrasonore Doppler. 1974;213-240 Editions INSERM, Séminaire INSERM, Paris, France.
12. Purdy K.E., Arendshorst W.J. Iloprost inhibits inositol-1,4,5-trisphosphate-mediated calcium mobilization stimulated by angiotensin II in cultured preglomerular vascular smooth muscle cells. J Am Soc Nephrol. 12:2001;19-28.
13. Radauceanu A., Avignon A., Ribstein J., Monnier L. Use of a prostacyclin analogue in cholesterol crystal embolism. Diabet Med. 15:1998;262-263.
14. Scorza R., Rivolta R., Mascagni B., et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol. 24:1997;1944-1948.
15. Shindo H., Tawata M., Aida K., Onaya T. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostaglandins. 41:1991;85-96.
16. Shindo H., Tawata M., Yokomori N., et al. Iloprost decreases urinary albumin excretion rate in patients with diabetic nephropathy. Diabetes Res Clin Pract. 21:1993;115-122.
17. Effects of perioperative iloprost on patency of femorodistal bypass grafts. Eur J Vasc Endovasc Surg. 12:1996;363-371.